Catalytic topoisomerase II inhibitors in cancer therapy

Pharmacology and Therapeutics

Volumn 99, Issue 2, 2003, Pages 167-181

  Larsen, Annette K ^a   Escargueil, Alexandre E ^b   Skladanowski, Andrzej ^a,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Aclarubicin; Catalytic inhibitor; ICRF 187; Merbarone; Suramin; Topoisomerase II

Indexed keywords

1 (3 AMINO 1 PYRROLIDINYL) 2 FLUORO 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; 2 FLUORO 1 (3 NORVALYLAMINO 1 PYRROLIDINYL) 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; 2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACLARUBICIN; AMSACRINE; CAMPTOTHECIN; CISPLATIN; COUMAMYCIN; COUMARIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FLUOROURACIL; FOSTRIECIN; GYRASE INHIBITOR; MERBARONE; MITOXANTRONE; NOVOBIOCIN; PIPERAZINE DERIVATIVE; QUINOBENZOXAZINE; QUINOLONE DERIVATIVE; RAZOXANE; SOBUZOXANE; SURAMIN; TENIPOSIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CATALYSIS; DNA BINDING; DRUG ACTIVITY; DRUG BINDING; DRUG TARGETING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0042346439     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(03)00058-5     Document Type: Review

References (124)

1. Ali-Osman F., Berger M.S., Rajagopal S., Spence A., Livingston R.B. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res. 53:1993;5663-5668.
2. Anderson H., Roberge M. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Cell Growth Differ. 7:1996;83-90.
3. Andoh T., Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta. 1400:1998;155-171.
4. Andreassen P.R., Martineau S.N., Margolis R.L. Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. Mutat Res. 372:1996;181-194.
5. Baird C.L., Harkins T.T., Morris S.K., Lindsley J.E. Topoisomerase II drives DNA transport by hydrolyzing one ATP. Proc Natl Acad Sci USA. 96:1999;13685-13690.
6. Barret J.M., Calsou P., Larsen A.K., Salles B. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Mol Pharmacol. 46:1994;431-436.
7. Benini S., Manara M.C., Baldini N., Cerisano V., Serra M., Mercuri M., Lollini P.L., Nanni P., Picci P., Scotlandi K. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. 7:2001;1790-1797.
8. Berger J.M., Gamblin S.J., Harrison S.C., Wang J.C. Structure and mechanisms of DNA topoisomerase II. Nature. 379:1996;225-232.
9. Bojanowski K., Lelievre S., Markovits J., Couprie J., Jacquemin-Sablon A., Larsen A.K. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA. 89:1992;3025-3029.
10. Boritzki T.J., Wolfard T.S., Besserer J.A., Jackson R.C., Fry D.W. Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol. 37:1988;4063-4068.
11. Bridewell D.J., Finlay G.J., Baguley B.C. Differential actions of aclarubicin and doxorubicin: The role of topoisomerase I. Oncol Res. 9:1997;535-542.
12. Brino L., Urzhumtsev A., Mousli M., Bronner C., Mitchler A., Oudet P., Moras D. Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center. J Biol Chem. 275:2000;9468-9475.
13. Calvo E., Cortes J., Rodriguez J., Sureda M., Beltran C., Rebollo J., Martinez-Monge R., Berian J.M., de Irala J., Brugarolas A. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma; a multicenter phase II study. Cancer. 92:2001;2435-2443.
14. Chang S., Hu T., Hsieh T.S. Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. J Biol Chem. 273:1998;19822-19828.
15. Chen M., Beck W.T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 53:1993;5946-5953.
16. Chen M., Beck W.T. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res. 55:1995;1509-1516.
17. Cheng A., Balczon R., Zuo Z., Koons J.S., Walsh A.H., Honkanen R.E. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity. Cancer Res. 58:1998;3611-3619.
18. Chu D.T., Hallas R., Clement J.J., Alder J., McDonald E., Plattner J.J. Synthesis and antitumour activities of quinolone antineoplastic agents. Drugs Exp Clin Res. 18:1992;275-282.
19. Chu D.T., Hallas R., Tanaka S.K., Alder J., Balli D., Plattner J.J. Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents. Drugs Exp Clin Res. 20:1994;177-183.
20. Clarke D.J., Johnson R.T., Downes C.S. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci. 105:1993;563-569.
21. Cocker H.A., Tiffin N., Pritchard-Jones K., Pinkerton C.R., Kelland L.R. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res. 7:2001;3193-3198.
22. Cooney D.A., Covey J.M., Kang G.J., Dalal M., McMahon J.B., Johns D.G. Initial mechanistic studies with merbarone (NSC 336628). Biochem Pharmacol. 34:1985;3395-3398.
23. Creighton A.M., Hellmann K., Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature. 222:1969;384-385.
24. Davies S.L., Bergh J., Harris A.L., Hickson I.D. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Br J Cancer. 75:1997;816-821.
25. de Jong R.S., Mulder N.H., Uges D.R., Sleijfer D.T., Hoppener F.J., Groen H.J., Willemse P.H., van der Graaf W.T., de Vries E.G. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Br J Cancer. 79:1999;882-887.
26. Deming P.B., Cistulli C.A., Zhao H., Graves P.R., Piwnica-Worms H., Paules R.S., Downes C.S., Kaufmann W.K. The human decatenation checkpoint. Proc Natl Acad Sci USA. 98:2001;12044-12049.
27. Downes C.S., Clarke D.J., Mullinger A.M., Gimenez-Abian J.F., Creighton A.M., Johnson R.T. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature. 372:1994;467-470.
28. Doyle L.A., Wei D., Yang W., Nakanishi T., Ross D.D. Modulation of mitoxantrone, daunorubicin, topotecan, and flavopiridol cytotoxicity in BCRP-expressing cancer cells by novobiocin. Proc Am Assoc Cancer Res. 43:2002;3857.
29. Drake F.H., Hofmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 28:1989;8154-8160.
30. Drake F.H., Hofmann G.A., Mong S.M., Bartus J.O., Hertzberg R.P., Johnson R.K., Mattern M.R., Mirabelli C.K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 49:1989;2578-2583.
31. Eder J.P. Jr., Chan V.T., Ng S.W., Rizvi N.A., Zacharoulis S., Teicher B.A., Schnipper L.E. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res. 55:1995;6109-6116.
32. Eisenberger M.A., Reyno L.M. Suramin. Cancer Treat Rev. 20:1994;259-273.
33. Escargueil A.E., Plisov S.Y., Skladanowski A., Borgne A., Meijer L., Gorbsky G.J., Larsen A.K. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J. 15:2001;2288-2290.
34. Evans D.R., Simon J.A. The predicted β12-β13 loop is important for inhibition of PP2Acα by the antitumor drug fostriecin. FEBS Lett. 498:2001;110-115.
35. Fiser-Littell R.M., Hanas J.S. Novobiocin inhibits Xenopus transcription factor IIIA-DNA interactions. J Biol Chem. 262:1987;11916-11919.
36. Fortune J.M., Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem. 273:1998;17643-17650.
37. Fry D.W., Besserer J.A., Boritzki T.J. Transport of the antitumor antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res. 44:1984;3366-3370.
38. Gieseler F., Bauer E., Nuessler V., Clark M., Valsamas S. Molecular effects of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage. Leukemia. 13:1999;1859-1863.
39. Glover A., Chun H.G., Kleinman L.M., Cooney D.A., Plowman J., Grieshaber C.K., Malspeis L., Leyland-Jones B. Merbarone: an antitumor agent entering clinical trials. Invest New Drugs. 5:1987;137-143.
40. Gorbsky G.J. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res. 54:1994;1042-1048.
41. Gormley N.A., Orphanides G., Meyer A., Cullis P.M., Maxwell A. The interaction of coumarin antibiotics with fragments of DNA gyrase B protein. Biochemistry. 35:1996;5083-5092.
42. Grossman S.A., Phuphanich S., Lesser G., Rozental J., Grochow L.B., Fisher J., Piantadosi S. New approaches to brain tumor therapy CNS consortium. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol. 19:2001;3260-3266.
43. Guo X.W., Th'ng J.P., Swank R.A., Anderson H.J., Tudan C., Bradbury E.M., Roberge M. Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J. 14:1995;976-985.
44. Hahm H.A., Armstrong D.K., Chen T.L., Grochow L., Passos-Coelho J., Goodman S.N., Davidson N.E., Kennedy M.J. Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study. Biol Blood Marrow Transplant. 6:2000;335-343.
45. Haraguchi T., Kaneda T., Hiraoka Y. Dynamics of chromosomes and microtubules visualized by multiple-wavelength fluorescence imaging in living mammalian cells: Effects of mitotic inhibitors on cell cycle progression. Genes Cells. 2:1997;369-380.
46. Hasinoff B.B., Kuschak T.I., Yalowich J.C., Creighton A.M. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol. 50:1995;953-958.
47. Hasinoff B.B., Yalowich J.C., Ling Y., Buss J.L. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs. 7:1996;558-567.
48. Hasinoff B.B., Kuschak T.I., Creighton A.M., Fattman C.L., Allan W.P., Thampatty P., Yalowich J.C. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol. 53:1997;1843-1853.
49. Hasinoff B.B., Hellmann K., Herman E.H., Ferrans V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem. 5:1998;1-28.
50. Hasinoff B.B., Abram M.E., Chee G.L., Huebner E., Byard E.H., Barnabe N., Ferrans V.J., Yu Z.X., Yalowich J.C. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. J Pharmacol Exp Ther. 295:2000;474-483.
51. Hasinoff B.B., Abram M.E., Barnabe N., Khelifa T., Allan W.P., Yalowich J.C. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 59:2001;453-461.
52. Hastie C.J., Cohen P.T. Purification of protein phosphatase 4 catalytic subunit: Inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. FEBS Lett. 431:1998;357-361.
53. Hellmann K., Burrage K. Control of malignant metastases by ICRF l59. Nature. 224:1969;273-275.
54. Herman E.H., Zhang J., Hasinoff B.B., Chadwick D.P., Clark J.R. Jr., Ferrans V.J. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol. 40:1997;400-408.
55. Hirota H., Gosky D., Berger N.A., Chatterjee S. Interference with topoisomerase II alpha potentiates melphalan cytotoxicity. Int J Oncol. 20:2002;311-318.
56. Ho D.T., Roberge M. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization. Carcinogenesis. 17:1996;967-972.
57. Hochster H., Liebes L., Wadler S., Oratz R., Wernz J.C., Meyers M., Green M., Blum R.H., Speyer J.L. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst. 84:1992;1725-1730.
58. Holm B., Sehested M., Jensen P.B. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res. 4:1998;1367-1373.
59. Hu T., Sage H., Hsieh T.S. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. J Biol Chem. 277:2002;5944-5951.
60. Huang K.C., Gao H., Yamasaki E.F., Grabowski D.R., Liu S., Shen L.L., Chan K.K., Ganapathi R., Snapka R.M. Topoisomerase II poisoning by ICRF-193. J Biol Chem. 276:2001;44488-44494.
61. Inutsuka S., Baba H., Maehara Y., Sugimachi K. MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines. Cancer Chemother Pharmacol. 42:1998;194-200.
62. Ishida R., Miki T., Narita T., Yui R., Sato M., Utsumi K.R., Tanabe K., Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 51:1991;4909-4916.
63. Ishida R., Sato M., Narita T., Utsumi K.R., Nishimoto T., Morita T., Nagata H., Andoh T. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol. 126:1994;1341-1351.
64. Ishida R., Iwai M., Hara A., Andoh T. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Anticancer Res. 16:1996;2735-2740.
65. Itzhaki J.E., Gilbert C.S., Porter A.C.G. Construction by gene targeting in human cells of a conditional CDC2 mutant that rereplicates its DNA. Nat Genet. 15:1997;258-265.
66. Iwai M., Hara A., Andoh T., Ishida R. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells. FEBS Lett. 406:1997;267-270.
67. Jackson R.C., Fry D.W., Boritzki T.J., Roberts B.J., Hook K.E., Leopold W.R. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regul. 23:1985;193-215.
68. Jensen L.H., Nitiss K.C., Rose A., Dong J., Zhou J., Hu T., Osheroff N., Jensen P.B., Sehested M., Nitiss J.L. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J Biol Chem. 275:2000;2137-2146.
69. Jensen L.H., Wessel I., Moller M., Nitiss J.L., Sehested M., Jensen P.B. N-terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance. FEBS Lett. 480:2000;201-207.
70. Kallio M., Lahdetie J. Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: Cell cycle arrest and induction of aneuploidy. Environ Mol Mutagen. 29:1997;16-27.
71. Kennedy M.J., Armstrong D.K., Huelskamp A.M., Ohly K., Clarke B.V., Colvin O.M., Grochow L.B., Chen T.L., Davidson N.E. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol. 13:1995;1136-1143.
72. Khelifa T., Beck W.T. Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells. Biochem Pharmacol. 58:1999;1247-1257.
73. Kizaki H., Onishi Y. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells. Adv Enzyme Regul. 37:1997;403-423.
74. Knox J.J., Moore M.J. Treatment of hormone refractory prostate cancer. Semin Urol Oncol. 19:2001;202-211.
75. Kobayashi M., Adachi N., Aratani Y., Kikuchi A., Koyama H. Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett. 166:2001;71-77.
76. Kung A.L., Sherwood S.W., Schimke R.T. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA. 87:1990;9553-9557.
77. Larsen A.K. Involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation. Ann Oncol. 5:1994;679-688.
78. Larsen A.K., Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death. Biochim Biophys Acta. 1400:1998;257-274.
79. Larsen A.K., Skladanowski A., Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Meijer L., Guidet S., Vogel L. Progress in Cell Cycle Research. vol. 2:1996;229-239 Plenum, New York.
80. Larsen A.K., Gobert C., Gilbert C., Markovits J., Bojanowski K., Skladanowski A. DNA topoisomerases as repair enzymes: mechanism(s) of action and regulation by p53. Acta Biochim Pol. 45:1998;535-544.
81. Larsen A.K., Escargueil A.E., Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther. 85:2000;217-229.
82. Larsen A.K., Gilbert C., Chyzak G., Plisov S.Y., Naguibneva I., Lavergne O., Lesueur-Ginot L., Bigg D.C.H. Unusual potency of BN 80915, a novel fluorinated homocamptothecin, toward human colon carcinoma cells. Cancer Res. 61:2001;2961-2967.
83. Lelievre S., Benchokroun Y., Larsen A.K. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Mol Pharmacol. 47:1995;898-906.
84. Leopold W.R., Shillis J.L., Mertus A.E., Nelson J.M., Roberts B.J., Jackson R.C. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res. 44:1984;1928-1932.
85. Li T.K., Chen A.Y., Yu C., Mao Y., Wang H., Liu L.F. Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress. Genes Dev. 13:1999;1553-1560.
86. Lodhi I.J., Clift R.E., Omann G.M., Sweeney J.F., McMahon K.K., Hinshaw D.B. Inhibition of mono-ADP-ribosyltransferase activity during the execution phase of apoptosis prevents apoptotic body formation. Arch Biochem Biophys. 387:2001;66-77.
87. Mamber S.W., Okasinski W.G., Pinter C.D., Tunac J.B. Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271. J Antibiot (Tokyo). 39:1986;1467-1472.
88. Monnot M., Mauffret O., Simon V., Lescot E., Psaume B., Saucier J.M., Charra M., Belehradek J. Jr., Fermandjian S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem. 266:1991;1820-1829.
89. 2/M checkpoint and apoptotic responses. Mol Pharmacol. 57:2000;296-307.
90. 2 and M phases of the cell cycle. Mol Cell Biol. 18:1998;5797-5808.
91. Murren J.R., DiStasio S.A., Lorico A., McKeon A., Zuhowski E.G., Egorin M.J., Sartorelli A.C., Rappa G. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies. Cancer J. 6:2000;256-265.
92. Nitiss J.L., Pourquier P., Pommier Y. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res. 57:1997;4564-4569.
93. Okamoto T., Nishimura Y., Yamada S., Yamada S., Itoh T., Mori A., Saheki K., Okada M., Takatsuka H., Wada H., Tamura A., Fujimori Y., Kakishita E. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol. 104:2000;128-130.
94. Permana P.A., Snapka R.M., Shen L.L., Chu D.T., Clement J., Plattner J.J. Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry. 33:1994;11333-11339.
95. Perrin D., van Hille B., Hill B.T. Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents. Biochem Pharmacol. 56:1998;503-507.
96. Petersen L.N., Jensen P.B., Sorensen B.S., Engelholm S.A., Spang-Thomsen M. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16. Invest New Drugs. 12:1994;289-297.
97. Qu G., Croghan G.M., Conover C., Erlichman C., Reid J.M., Burch P.A., Sloan J.A., Pitot H.C., Hanson L.J., Atherton P., Ames M.M., Adjei A.A. A phase I and pharmacologic study of suramin with sequential adriamycin in patients with advanced solid tumors. Proc Am Assoc Cancer Res. 3:2002;402.
98. Rappa G., Lorico A., Sartorelli A.C. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Cancer Res. 52:1992;2782-2790.
99. Rappa G., Lorico A., Sartorelli A.C. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Cancer Res. 53:1993;5487-5493.
100. Rappa G., Murren J.R., Johnson L.M., Lorico A., Sartorelli A.C. Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells. Anticancer Drug Res. 15:2000;127-134.
101. Rattner J.B., Hendzel M.J., Furbee C.S., Muller M.T., Bazett-Jones D.P. Topoisomerase II alpha is associated with the mammalian centromere in a cell cycle- and species-specific manner and is required for proper centromere/kinetochore structure. J Cell Biol. 134:1996;1097-1107.
102. Roberge M., Tudan C., Hung S.M., Harder K.W., Jirik F.R., Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res. 54:1994;6115-6121.
103. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA. 91:1994;1781-1785.
104. Sargent J.M., Williamson C.J., Yardley C., Taylor C.G., Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer. 84:2001;959-964.
105. Sato M., Ishida R., Narita T., Kato J., Ikeda H., Fukazawa H., Andoh T. Interaction of the DNA topoisomerase II catalytic inhibitor meso-2,3-bis(3,5-dioxopiperazine-1-yl)butane (ICRF-193), a bisdioxopiperazine derivative, with the conserved region(s) of eukaryotic but not prokaryotic enzyme. Biochem Pharmacol. 54:1997;545-550.
106. Sato M., Ishida R., Ohsumi K., Narita T., Andoh T. DNA topoisomerase II as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract. Biochem Biophys Res Commun. 235:1997;571-575.
107. Sehested M., Wessel I., Jensen L.H., Holm B., Oliveri R.S., Kenwrick S., Creighton A.M., Nitiss J.L., Jensen P.B. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res. 58:1998;1460-1468.
108. Sekiguchi J., Stivers J.T., Mildvan A.S., Shuman S. Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin. J Biol Chem. 271:1996;2313-2322.
109. Shiozawa K., Oka M., Nakatomi K., Yoshikawa M., Ikegami Y., Kawabata S., Soda H., Tsurutani J., Murase K., Kohno S. Effective reversal of breast cancer resistant protein (BCRP)-mediated drug resistance by novobiocin. Proc Am Assoc Cancer Res. 43:2002;2460.
110. Song S., Wientjes M.G., Gan Y., Au J.L. Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA. 97:2000;8658-8663.
111. Song S., Wientjes M.G., Walsh C., Au J.L. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res. 61:2001;6145-6150.
112. Sorensen B.S., Sinding J., Andersen A.H., Alsner J., Jensen P.B., Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol. 228:1992;778-786.
113. Sorensen B.S., Jensen P.B., Sehested M., Jensen P.S., Kjeldsen E., Nielsen O.F., Alsner J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: Role of topoisomerase I. Biochem Pharmacol. 47:1994;2105-2110.
114. Swain S.M., Whaley F.S., Gerber M.C., Ewer M.S., Bianchine J.R., Gams R.A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Clin Oncol. 15:1997;1333-1340.
115. Synold T.W., Tetef M.L., Doroshow J.H. Antineoplastic activity of continuous exposure to dexrazoxane: Potential new role as a novel topoisomerase II inhibitor. Semin Oncol. 25(Suppl. 10):1998;93-99.
116. Tanabe K., Ikegami Y., Ishida R., Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51:1991;4903-4908.
117. Traganos F., Darzynkiewicz Z., Melamed M.R. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res. 41:1981;4566-4576.
118. Walsh A.H., Cheng A., Honkanen R.E. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett. 416:1997;230-234.
119. Wessel I., Jensen L.H., Jensen P.B., Falck J., Rose A., Roerth M., Nitiss J.L., Sehested M. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the α isoform. Cancer Res. 59:1999;3442-3450.
120. Yalowich J.C., Thampatty P., Allan W.P., Chee G.L., Hasinoff B.B. Acquired resistance to ICRF-187 (dexrazoxane) in a CHO line is associated with a point mutation in DNA topoisomerase II alpha and decreased drug-induced DNA-enzyme complexes. Proc Am Assoc Cancer Res. 39:1998;375.
121. Yang B., Strode J.T., Spielmann H.P., Wang A.H.J., Burke T.G. DNA interactions stabilize their active lactone form. J Am Chem Soc. 120:1998;2979-2980.
122. Yoshida M., Maehara Y., Sugimachi K. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. Clin Cancer Res. 5:1999;4295-4300.
123. Zhang Y., Song S., Yang F., Au J.L., Wientjes M.G. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther. 299:2001;426-433.
124. Zwilling B.S., Campolito L.B., Reiches N.A., George T., Witiak D.T. Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma. Br J Cancer. 44:1981;578-583.